CO2019014286A2 - Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas - Google Patents

Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas

Info

Publication number
CO2019014286A2
CO2019014286A2 CONC2019/0014286A CO2019014286A CO2019014286A2 CO 2019014286 A2 CO2019014286 A2 CO 2019014286A2 CO 2019014286 A CO2019014286 A CO 2019014286A CO 2019014286 A2 CO2019014286 A2 CO 2019014286A2
Authority
CO
Colombia
Prior art keywords
bis
protein conjugates
octahydrophenanthrene
carboxamides
octahydrophenanthrene carboxamides
Prior art date
Application number
CONC2019/0014286A
Other languages
English (en)
Inventor
Amy Han
William Olson
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62245504&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019014286(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2019014286A2 publication Critical patent/CO2019014286A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated

Abstract

En el presente documento se proporcionan compuestos, composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con el receptor X del hígado, incluidas las bis-octahidrofenantrenocarboxamidas y sus conjugados de proteínas (por ejemplo, anticuerpos).
CONC2019/0014286A 2017-05-18 2019-12-17 Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas CO2019014286A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508327P 2017-05-18 2017-05-18
PCT/US2018/031910 WO2018213082A1 (en) 2017-05-18 2018-05-09 Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

Publications (1)

Publication Number Publication Date
CO2019014286A2 true CO2019014286A2 (es) 2020-04-01

Family

ID=62245504

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0014286A CO2019014286A2 (es) 2017-05-18 2019-12-17 Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas

Country Status (16)

Country Link
US (2) US20180334426A1 (es)
EP (1) EP3625209A1 (es)
JP (2) JP2020520926A (es)
KR (1) KR20200008579A (es)
CN (1) CN111065622A (es)
AU (1) AU2018269568B2 (es)
BR (1) BR112019023990A2 (es)
CA (1) CA3063872A1 (es)
CL (1) CL2019003270A1 (es)
CO (1) CO2019014286A2 (es)
EA (1) EA201900562A1 (es)
IL (1) IL270595B2 (es)
MA (1) MA47392B1 (es)
MX (1) MX2019013693A (es)
PH (1) PH12019502576A1 (es)
WO (1) WO2018213082A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
KR20200085807A (ko) * 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
EA202191430A1 (ru) 2018-11-20 2021-11-29 Регенерон Фармасьютикалз, Инк. Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты
WO2020146541A2 (en) * 2019-01-08 2020-07-16 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
CA3179154A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
EP4172141A1 (en) * 2020-06-26 2023-05-03 Synaffix B.V. Methods for the preparation of linker payload constructs
JP2023548975A (ja) 2020-11-10 2023-11-21 レジェネロン ファーマシューティカルズ， インコーポレイテッド セレン抗体複合体
CN112661783B (zh) * 2020-12-28 2022-06-07 中国林业科学研究院林产化学工业研究所 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用
CN115006390B (zh) * 2022-06-27 2024-04-19 国药集团动物保健股份有限公司 一种病毒减毒制剂、其制备方法以及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
CA2392568A1 (en) * 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
JP2008503547A (ja) * 2004-06-24 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨ホメオスタシスを促進させる方法及び組成物
US7238791B1 (en) * 2005-12-16 2007-07-03 Roche Diagnostics Operations, Inc. 6-monoacetylmorphine derivatives useful in immunoassay
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
ES2731432T3 (es) 2007-05-23 2019-11-15 Ventana Med Syst Inc Transportadores poliméricos para inmunohistoquímica e hibridación in situ
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP2632947A4 (en) 2010-10-29 2015-03-18 Immunogen Inc NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EA036202B1 (ru) 2011-10-14 2020-10-14 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
AU2012322933B2 (en) 2011-10-14 2017-02-02 Medimmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
JP6855661B2 (ja) 2012-10-23 2021-04-07 シンアフィックス ビー．ブイ． 修飾抗体、抗体コンジュゲート及びそれらを調製する方法
US20150238631A1 (en) * 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20160324981A1 (en) * 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
US11786603B2 (en) 2016-02-26 2023-10-17 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
CA3098453A1 (en) * 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2018269568A1 (en) 2020-01-16
MX2019013693A (es) 2020-01-27
WO2018213082A1 (en) 2018-11-22
KR20200008579A (ko) 2020-01-28
US20220112158A1 (en) 2022-04-14
EA201900562A1 (ru) 2020-05-12
JP2020520926A (ja) 2020-07-16
IL270595B2 (en) 2023-09-01
IL270595B1 (en) 2023-05-01
IL270595A (es) 2019-12-31
EP3625209A1 (en) 2020-03-25
US20180334426A1 (en) 2018-11-22
JP2023113639A (ja) 2023-08-16
CN111065622A (zh) 2020-04-24
AU2018269568B2 (en) 2022-03-24
BR112019023990A2 (pt) 2020-06-16
CA3063872A1 (en) 2018-11-22
PH12019502576A1 (en) 2020-09-28
CL2019003270A1 (es) 2020-05-08
MA47392A1 (fr) 2020-10-28
MA47392B1 (fr) 2021-09-30

Similar Documents

Publication Publication Date Title
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
CY1124293T1 (el) Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου
CO2020006248A2 (es) Moduladores de la vía de estrés integrada
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
BR112019012342A2 (pt) anticorpos il-11
CO2020006227A2 (es) Moduladores de la vía de estrés integrada
UY37230A (es) Moduladores de la vía de estrés integrada
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
UY37231A (es) Moduladores de la vía de estrés integrada
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
UY37229A (es) Moduladores de la vía de estrés integrada
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
MX2019004690A (es) Constructos de anticuerpos.
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
PH12020551716A1 (en) Anti-ror antibody constructs
CO2021007581A2 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteínas de los mismos para usarse como agonistas de lxr
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2022001970A1 (es) Conjugados de proteínas-compuestos antivirales